AGEN · TickerCove

AGENAgenus Inc.Healthcare · Biotechnologyas of 2026-09-25

Horizon

Issued 2026-09-25 at $8.54 · now $8.54 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, AGEN has typically landed between $5.67 and $12.70 — a range of −33.6% to +48.7% from the issuance price $8.54.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

5,007 overlapping 1 month windows · 2006-09-26 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($8.54) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$8.54 · 97% of range

$2.77 low$8.7 high

Trailing 52 weeks to 2026-09-25 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,391 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.7%

90% CI 51.5%–55.9%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−5.1%

typical move · IQR 30.4%

−33.6%worst (p90)+48.7%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where AGEN has typically landed a month from the 2026-09-25 close of $8.54 — the range is history, not a prediction.

now $8.54 (+0.0%)
typical $8.1 (-5.1%)
middle 50% $6.8–$9.4
90% range $5.67–$12.7

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 5,007 windows spanning 2006-09-26 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2024-07-16	−74.1%	−74.1%	+0.2%
2024-07-17	−70.8%	−74.2%	+0.0%
2024-07-15	−69.8%	−69.8%	+13.7%
3 best
2009-05-01	+267.8%	−25.6%	+267.8%
2009-05-26	+246.2%	+0.0%	+394.3%
2009-05-07	+228.2%	−23.9%	+276.1%

5,007 overlapping windows · 2006-09-26 – 2026-09-25 · not cherry-picked

Pending catalysts

September 2027 — Trial primary completion: Phase 2 primary completion: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (source, as of 2026-08-14)
February 2028 — Trial primary completion: Phase 2 primary completion: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

60%

+6.2%

n=20

Feb

50%

+2.5%

n=20

Mar

35%

+0.1%

n=20

Apr

55%

+11.7%

n=20

May

50%

+4.7%

n=20

Jun

65%

+11.1%

n=20

Jul

55%

+6.1%

n=20

Aug

35%

−2.6%

n=20

Sep

30%

−4.4%

n=20

Oct

25%

−11.8%

n=20

Nov

45%

+1.6%

n=20

Dec

20%

−5.4%

n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

156 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-08-10	ARMEN GARO H	director	Award / grant	1,971,500	1,971,500	Form 4
2026-08-05	Corvese Brian	director	Award / grant	100,000	100,000	Form 4
2026-08-05	Hirsch Susan B	director	Award / grant	50,000	50,000	Form 4
2026-08-05	O'Day Steven J	officer	Award / grant	100,000	100,000	Form 4
2026-08-05	Wright Timothy	director	Award / grant	50,000	50,000	Form 4
2026-08-05	Buell Jennifer	director	Award / grant	200,000	200,000	Form 4
2026-08-05	Marcucci Marco Tullio	director	Award / grant	7,500	7,500	Form 4
2026-08-05	HARRISON THOMAS L	director	Award / grant	50,000	50,000	Form 4
2026-07-10	ARMEN GARO H	director	Award / grant	4,852	371,108	Form 4
2026-07-01	HARRISON THOMAS L	director	Award / grant	8,547	47,545	Form 4
2026-07-01	Wright Timothy	director	Award / grant	2,268	26,181	Form 4
2026-07-01	Wright Timothy	director	Award / grant	2,268	26,181	Form 4
2026-06-26	ARMEN GARO H	director	Award / grant	5,364	366,256	Form 4
2026-06-12	ARMEN GARO H	director	Award / grant	4,925	360,892	Form 4
2026-05-29	ARMEN GARO H	director	Award / grant	4,644	355,967	Form 4
2026-05-15	ARMEN GARO H	director	Award / grant	4,540	351,323	Form 4
2026-05-01	ARMEN GARO H	director	Award / grant	4,233	346,783	Form 4
2026-04-24	HARRISON THOMAS L	director	Award / grant	122,500	122,500	Form 4
2026-04-24	Buell Jennifer	director	Award / grant	300,000	300,000	Form 4
2026-04-24	Buell Jennifer	director	Award / grant	5,000	5,000	Form 4
2026-04-24	Corvese Brian	director	Award / grant	210,000	210,000	Form 4
2026-04-24	ARMEN GARO H	director	Award / grant	1,000,000	1,000,000	Form 4
2026-04-24	Charette Austin	officer	Award / grant	5,000	5,000	Form 4
2026-04-24	Charette Austin	officer	Award / grant	17,619	17,619	Form 4
2026-04-24	ARMEN GARO H	director	Award / grant	27,750	27,750	Form 4
2026-04-24	ARMEN GARO H	director	Award / grant	137,550	137,550	Form 4
2026-04-24	Hirsch Susan B	director	Award / grant	105,000	105,000	Form 4
2026-04-24	Wright Timothy	director	Award / grant	105,000	105,000	Form 4
2026-04-24	O'Day Steven J	officer	Award / grant	70,000	70,000	Form 4
2026-04-24	O'Day Steven J	officer	Award / grant	95,333	95,333	Form 4
2026-04-17	ARMEN GARO H	director	Award / grant	3,403	342,550	Form 4
2026-04-03	ARMEN GARO H	director	Award / grant	4,629	339,147	Form 4
2026-04-01	HARRISON THOMAS L	director	Award / grant	9,228	38,998	Form 4
2026-04-01	Wright Timothy	director	Award / grant	2,448	26,361	Form 4
2026-04-01	Wright Timothy	director	Award / grant	2,448	26,361	Form 4
2026-03-20	ARMEN GARO H	director	Award / grant	3,983	334,518	Form 4
2026-03-06	ARMEN GARO H	director	Award / grant	4,994	330,535	Form 4
2026-02-20	ARMEN GARO H	director	Award / grant	4,829	325,541	Form 4
2026-02-06	ARMEN GARO H	director	Award / grant	5,027	320,712	Form 4
2026-01-23	ARMEN GARO H	director	Award / grant	4,562	315,685	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

27d remaining

2026-09-2610% elapsed2026-10-26

Logged immutably 2026-09-26; scored automatically on 2026-10-26 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Pending catalysts

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i